Oxidoreductase (1. ) (e.g., Luciferase) Patents (Class 435/189)
  • Publication number: 20130011871
    Abstract: In one non-limiting aspect, sterilizable reagent materials for diagnostic elements are provided. In other aspects, sterilized diagnostic elements and techniques for the production of the same are disclosed. In one embodiment, a sterilized diagnostic element includes a chemical detection reagent including at least one component that is sensitive to ionizing radiation. The sterilized diagnostic element is also mediator-free and the at least one component sensitive to ionizing radiation is present in a functional form in a proportion of ? 80% based on the total amount of the respective component in the diagnostic element before sterilization. In certain aspects, the at least one component sensitive to ionizing radiation includes one or both of an enzyme and a coenzyme. Other aspects include, but are not limited to, unique methods, techniques, products, systems and devices involving sterilizable reagent materials or sterilized diagnostic elements.
    Type: Application
    Filed: June 11, 2012
    Publication date: January 10, 2013
    Inventors: Carina Horn, Nelli Steinke
  • Patent number: 8349599
    Abstract: Described are multimeric oxidoreductase complexes which function in the enzymatic conversion of a carbon substrate. The complexes having a dehydrogenase subunit and a cytochrome C subunit. Also described are polynucleotides coding for the multimeric complexes and methods of use thereof.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: January 8, 2013
    Assignee: Danisco US Inc.
    Inventors: Robert M. Caldwell, M. Harunur Rashid, Fernando Valle
  • Publication number: 20130005610
    Abstract: Genes and genetic variants in human genomes are disclosed which are useful, inter alia, as diagnostic biomarkers.
    Type: Application
    Filed: October 19, 2010
    Publication date: January 3, 2013
    Applicant: Myriad Genetics, Incorporated
    Inventor: Susanne Wagner
  • Publication number: 20130005666
    Abstract: The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Rajiv RATAN, Irina GAZARYAN, Natalya A. SMIRNOVA
  • Patent number: 8343744
    Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: January 1, 2013
    Assignee: The California Institute of Technology
    Inventors: Frances H Arnold, Matthew W Peters, Peter Meinhold
  • Publication number: 20120329131
    Abstract: A method for increasing the activity of superoxide dismutase comprises steps of: liquid culture, by providing a strain of Bacillus subtilis and a liquid medium to carry out a fed-batch fermentation and to obtain a primary fermentation broth, wherein the liquid medium has 8 wt % to 10 wt % of maltose, 10 wt % to 15 wt % of soya powder and rest of water; and solid culture, by culturing the primary fermentation broth in a solid medium, which has solid substrate and maltose in a ratio of 10:1 to 20:1, to obtain a secondary fermentation broth with SOD in high activity, wherein the solid substrate contains wheat germ and water.
    Type: Application
    Filed: June 22, 2011
    Publication date: December 27, 2012
    Inventors: Pao-Chuan HSIEH, Wan-Ting Su
  • Publication number: 20120329709
    Abstract: The present invention provides methods and materials by which glycosylation of glycoproteins can be regulated. Methods include the monitoring and regulation of parameters such that a glycoprotein having a desired product quality is obtained.
    Type: Application
    Filed: May 25, 2010
    Publication date: December 27, 2012
    Inventors: Brian Edward Collins, Tiffany Guo, Lakshmanan Thiruneelakantapillai, Kevin Millea, Dorota A. Bulik
  • Patent number: 8338152
    Abstract: Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta-8 desaturases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) and using these delta-8 desaturases in plants.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 25, 2012
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Howard Glenn Damude, Quinn Qun Zhu
  • Publication number: 20120322136
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 20, 2012
    Applicant: CODEXIS, INC.
    Inventors: Emily Mundorff, Erik De Vries
  • Publication number: 20120315629
    Abstract: Described are cell surface and circulating markers for aging related disorders (specific isoforms of NADH oxidase (arNOX)). Recombinant age-related NADH oxidase isoforms and their coding sequences and methods for detecting arNOX isoform presence and quantitation in tissues and in blood, sera, urine, saliva, perspiration and in other body fluids, are provided. Recombinant arNOX proteins are useful in preparing antigens for use in the generation of monoclonal and polyclonal antibodies as well as immunogenic compositions for diagnosis and treatment of aging disorders. DNA probes based on the DNA sequence information provide may be used to identify individuals at risk for aging disorders and for development of therapeutic interventions or anti-aging cosmetic or other formulations of benefit in slowing the aging process in mammals.
    Type: Application
    Filed: August 17, 2010
    Publication date: December 13, 2012
    Applicant: Nox Technologies ,Inc.
    Inventors: D. James Morre, Xiaoyu Tang, Sara Dick, Christiaan Meadows, Dorothy M. Morre
  • Patent number: 8329872
    Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: December 11, 2012
    Assignee: Novartis AG
    Inventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
  • Patent number: 8329438
    Abstract: The disclosure relates to engineered enone reductase polypeptides having improved properties, polynucleotides encoding the engineered polypeptides, related vectors, host cells, and methods for making the engineered enone reductase polypeptides. The disclosure also provides methods of using the engineered enone reductase polypeptides for chemical transformations.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 11, 2012
    Assignee: Codexis, Inc.
    Inventors: Christopher Savile, Vesna Mitchell, Xiyun Zhang, Gjalt Huisman
  • Patent number: 8329439
    Abstract: A modified pyrroloquinoline quinone glucose dehydrogenase that exhibits a high selectivity for glucose is provided. A modified pyrroloquinoline quinone glucose dehydrogenase is disclosed in which the amino acid residue G at Position 99 of a pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 1, or the amino acid residue G at Position 100 of the pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 3, is substituted by the amino acid sequence TGZN (where Z is SX, S, or N and X is any amino acid residue). The modified PQQGDH of the present invention may additionally comprise one or more mutations selected from the group consisting of Q192G, Q192A, or Q192S; L193X; E277X; A318X; Y367A, Y367F, or Y367W; G451C; and N452X (where X is any amino acid residue).
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: December 11, 2012
    Assignees: ARKRAY, Inc., Ultizyme International Ltd.
    Inventor: Koji Sode
  • Patent number: 8323936
    Abstract: The invention relates to a process for the enantioselective enzymatic reduction of secodione derivatives. The secodione derivative is reduced with an oxidoreductase/dehydrogenase in the presence of NADH or NADPH as a cofactor. The secodione derivative is used in the reaction batch at a concentration of ?10 g/l and the oxidized cofactor NAD or NADP formed by the oxidoreductase/dehydrogenase is regenerated continuously.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: December 4, 2012
    Assignee: IEP GmbH
    Inventors: Antje Gupta, Anke Tschentscher, Maria Bobkova
  • Patent number: 8323924
    Abstract: Compositions and methods for producing aldehydes, alkanes, and alkenes are described herein. The aldehydes, alkanes, and alkenes can be used in biofuels.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: December 4, 2012
    Assignee: LS9, Inc.
    Inventors: Andreas Schirmer, Mathew Rude, Shane Brubaker
  • Publication number: 20120301919
    Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Applicant: Agency for Science, Technology and Research
    Inventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
  • Publication number: 20120295324
    Abstract: Methods, compositions, and systems for overproducing ligninolytic enzymes from the basidiomycetous fungus are described herein. As described, the method can include incubating a fungal strain of Cerrena unicolor IB303 in a fermentation system having growth medium which includes lignocellulosic material and then cultivating the fungal strain in the fermentation system under conditions wherein the fungus expresses the ligninolytic enzymes. In some cases, the lignocellulosic material is mandarin peel, ethanol production residue, walnut pericarp, wheat bran, wheat straw, or banana peel.
    Type: Application
    Filed: May 4, 2012
    Publication date: November 22, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Vladimir Elisashvili, Eva Kachlishvili, Tamas Torok
  • Publication number: 20120295252
    Abstract: A composition for analyzing nucleic acid that contains luciferase for which reactivity to dATP is equal to or less than 1/400 reactivity to ATP. A method for analyzing nucleic acid that comprises the use of the composition. A kit for analyzing nucleic acid comprising the composition. The method provides for an inexpensive, highly accurate and highly sensitive nucleic acid analysis that uses dATP instead of an expensive reagent having a low reactivity to DNA polymerase.
    Type: Application
    Filed: June 20, 2011
    Publication date: November 22, 2012
    Applicant: Kikkoman Corporation
    Inventors: Shigeya Suzuki, Yukako Kodama, Keiko Kurosawa, Eiry Kobatake, Masayasu Mie
  • Publication number: 20120295326
    Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 22, 2012
    Applicants: The Board of Trustees of the Leland Stanford Junior University, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
  • Publication number: 20120295325
    Abstract: A firefly luciferase having the amino acid sequence of firefly luciferase, wherein the amino acid corresponding to position 287 of Heike firefly luciferase is replaced with alanine, or wherein the amino acid corresponding to position 392 is replaced with isoleucine. The firefly luciferase has improved thermostability and storage stability. A firefly luciferase gene coding for the firefly luciferase. By utilizing this gene, it is possible to efficiently produce firefly luciferase with increased stability. It is also possible to obtain firefly luciferase with further increased stability by combination with a mutation in which the amino acid at position 326 is replaced with serine, and/or a mutation in which the amino acid at position 467 is replaced with isoleucine.
    Type: Application
    Filed: February 16, 2010
    Publication date: November 22, 2012
    Applicant: KIKKOMAN CORPORATION
    Inventors: Yukako Kodama, Eriko Yoshihara
  • Patent number: 8313936
    Abstract: The present invention provides polypeptides involved in cryptophycin biosynthesis and the nucleic acid molecules that encode such polypeptides. The nucleic acid molecules and polypeptides of the invention or variants thereof can be used in the methods of the invention to produce cryptophycins.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 20, 2012
    Assignee: Regents of the University of Michigan
    Inventors: David H Sherman, Zachary Q Beck, Yousong Ding
  • Patent number: 8309328
    Abstract: The present application provides genetically modified fungal organisms that produce enzyme mixtures exhibiting enhanced hydrolysis of cellulosic material to glucose, enzyme mixtures produced by the genetically modified fungal organisms, and processes for producing glucose from cellulose using such enzyme mixtures.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: November 13, 2012
    Assignee: Codexis, Inc.
    Inventors: Ish Kumar Dhawan, Dipnath Baidyaroy, Andrew Shaw, Oleh Tanchak, Christopher Hill, Chengsong Liu, Amala Chokshi, Brian R. Scott
  • Patent number: 8304224
    Abstract: The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a ?-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: November 6, 2012
    Assignee: MedImmune Limited
    Inventor: Ann Lövgren
  • Publication number: 20120276247
    Abstract: The present invention relates to a newly identified lipase belonging to the Ustilaginaceae family of Basidomycetes and variants thereof. The invention also relates to polynucleotides encoding the lipase and the variants thereof. The invention further relates to procedures for producing the lipase, and variants thereof, polypeptides and polynucleotides. The invention further relates to lipase variants with an increased trans-selectivity. The invention further relates to lipase variants with a preference for long chain fatty acid esters or carboxylic acid moieties with a chain length greater than C12. The invention further relates to a method of reducing, or eliminating, trans-fatty acids from liquid oil stable enough for frying systems.
    Type: Application
    Filed: April 29, 2011
    Publication date: November 1, 2012
    Inventors: Uwe Bornscheuer, Henrike Brundiek, Andrew Evitt, Stefan Sass, Friedericke Bönisch, Robert Kourist
  • Publication number: 20120276610
    Abstract: The present invention relates to the isolation and characterization of a protein responsible for the reduction of uranium (VI) to uranium (IV). The present invention extends to the use of the isolated protein in the reduction of uranium (VI) to uranium (IV) and further extends to a process for the bioremediation, or at least partial remediation, of a site contaminated with a source of U (VI). According to a first aspect thereof, the present invention provides an isolated polypeptide derived from Thermus scotoductus strain SA-01 that is responsible for the reduction of uranium (VI), in a source of uranium (VI), to uranium (IV), wherein the polypeptide comprises the amino acid sequence of SEQ ID No: 1.
    Type: Application
    Filed: September 21, 2010
    Publication date: November 1, 2012
    Applicant: University of the Free State
    Inventors: Errol Duncan Cason, Esta Van Heerden, Lizelle Ann Piater, Abitha Gyanendra Jugdave, Jacqueline Van Marwijk
  • Publication number: 20120276145
    Abstract: A method of identifying a biofilm that includes non-typeable Haemophilus influenza (NTHi) including a step of screening a sample for the presence of one or more biofilm-specific proteins that are expressed by NTHi. In some cases, an NTHi biofilm-related disease in a subject is diagnosed. Also disclosed are protein microarrays for screening biofilm-specific proteins in a sample, formulations comprising one or more biofilm-specific proteins or fragments thereof, and methods for inducing an immune response in a patient against a biofilm-related infection.
    Type: Application
    Filed: March 27, 2012
    Publication date: November 1, 2012
    Applicant: HOUSE RESEARCH INSTITUTE
    Inventors: Paul Webster, Siva Wu, James Kerwin
  • Publication number: 20120276567
    Abstract: The invention relates to a Talaromyces transformant comprising one or more recombinant gene, capable of producing cellulase in the absence of cellulase inducer in a glucose medium, having a cellulase activity of 2 WSU/ml or more, in 16 times or more diluted supernatant or broth.
    Type: Application
    Filed: November 4, 2010
    Publication date: November 1, 2012
    Applicant: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Brenda Vonk, Marco Alexander Berg Van Den, Robbertus Antonius Damveld, Cornelis Maria Jacobus Sagt, Adrianus Wilhelmus Hermanus Vollebregt, Margot Elisabeth Francoise Schooneveld-Bergmans
  • Patent number: 8298812
    Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: October 30, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Silke Dlugai, Doerthe Voss, Eckhard Boles
  • Publication number: 20120270285
    Abstract: Stereospecific carbonyl reductases SCR1, SCR2, and SCR3 are described herein as are nucleotide sequences that encode these reductases. These stereospecific carbonyl reductases have anti-Prelog selectivity and have specificities that are useful for fine biochemical synthesis.
    Type: Application
    Filed: June 23, 2010
    Publication date: October 25, 2012
    Inventors: Gaetano T. Montelione, Rong Xiao, Yao Nie, Yan Xu
  • Patent number: 8293228
    Abstract: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: October 23, 2012
    Assignee: Savient Pharmaceuticals Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Publication number: 20120264179
    Abstract: The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 18, 2012
    Applicant: GENOMATICA, INC.
    Inventors: Anthony P. Burgard, Priti Pharkya, Robin E. Osterhout
  • Publication number: 20120266329
    Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.
    Type: Application
    Filed: February 20, 2012
    Publication date: October 18, 2012
    Applicant: BP Corporation North America Inc.
    Inventors: Eric J. Mathur, Cathy Chang
  • Publication number: 20120264169
    Abstract: The present invention relates to cells producing at least one polypeptide of interest and expressing one or more recombinant nuclease encoding gene(s) thereby producing the nuclease(s), and methods for producing a polypeptide of interest essentially free from contaminating DNA, said method comprising the steps of: (a) cultivating a cell that produces at least one polypeptide of interest and expresses one or more recombinant nuclease encoding gene(s) thereby producing the nuclease(s); and (b) isolating the polypeptide of interest.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Applicant: NOVOZYMES A/S
    Inventors: Michael Dolberg Rasmussen, Jon Martin Persson
  • Patent number: 8288147
    Abstract: Methods for synthesizing isopentenyl pyrophosphate are provided. A first method comprises introducing into a host microorganism a plurality of heterologous nucleic acid sequences, each coding for a different enzyme in the mevalonate pathway for producing isopentenyl pyrophosphate. A related method comprises introducing into a host microorganism an intermediate in the mevalonate pathway and at least one heterologous nucleic acid sequence, each sequence coding for an enzyme in the mevalonate pathway necessary for converting the intermediate into isopentenyl pyrophosphate. The invention also provides nucleic acid sequences, enzymes, expression vectors, and transformed host cells for carrying out the methods.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: October 16, 2012
    Assignee: The Regents of the University of California
    Inventors: Jay D. Keasling, Vincent J.J. Martin, Douglas J. Pitera, Seon-Won Kim, Sydnor T. Withers, III, Yasuo Yoshikuni, Jack Newman, Artem Valentinovich Khlebnikov
  • Patent number: 8288131
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of stereo specifically reducing (R)-2-methylpentanal to (R)-2-methylpentanol. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to produce (R)-2-methylpentanol and related compounds.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 16, 2012
    Assignees: Codexis, Inc., Pfizer, Inc.
    Inventors: Rama Voladri, Owen Gooding, Stephan Jenne, Emily Mundorff
  • Patent number: 8288141
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: October 16, 2012
    Assignee: Codexis, Inc.
    Inventors: Christopher Savile, John M. Gruber, Emily Mundorff, Gjalt Huisman, Steven James Collier
  • Patent number: 8283146
    Abstract: The invention is related to processing enzyme comprising an N-terminally attached tag derived from highly basic proteins from thermophilic bacteria. The processing enzymes are useful for modifying proteins. They can be produced in high yields and can be effectively separated from the modified protein after use.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: October 9, 2012
    Assignee: Novo Nordisk Health Care AG
    Inventor: Allan Christian Shaw
  • Publication number: 20120252093
    Abstract: Promoter regions associated with the Yarrowia lipolytica esterase/lipase (EL1) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 4, 2012
    Applicant: E I Du Pont De Nemours and Company
    Inventor: Quinn Qun Zhu
  • Publication number: 20120252064
    Abstract: The present invention is related to a fungal serine protease enzyme, which said enzyme has serine protease activity and comprises an amino acid sequence of Malbranchea ALKO4122 mature protease as defined in SEQ ID NO:18 or an amino acid sequence having at least 66% identity to the amino acid sequence of SEQ ID NO:18. Also disclosed is an isolated nucleic acid molecule, comprising a polynucleotide sequence which encodes a fungal serine protease enzyme, nucleic acid sequences encoding said protease, a host cell and a process of producing a polypeptide having serine protease activity. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, wool, hair, leather, or silk, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Application
    Filed: March 29, 2012
    Publication date: October 4, 2012
    Applicant: AB ENZYMES OY
    Inventors: Leena Valtakari, Kari Juntunen, Marja Paloheimo, Pentti Ojapalo
  • Publication number: 20120246760
    Abstract: Identification of a protein having an activity of oxidizing oleanane-type triterpene, and a gene encoding the protein, the protein and the gene, and use thereof are provided. For example, a protein having an activity of oxidizing oleanane-type triterpene obtained from a plant in the family Fabaceae, a gene encoding the protein and use thereof are provided. The protein is shown in, for example, SEQ ID NO: 4, 14 or 18, and the gene encoding the protein is shown in, for example, SEQ ID NO: 3, 13 or 17. A transformant into which the gene is introduced can be produced, and thereby a triterpene oxidase can be obtained.
    Type: Application
    Filed: August 31, 2009
    Publication date: September 27, 2012
    Applicant: RIKEN
    Inventors: Toshiya Muranaka, Hikaru Seki, Kiyoshi Ohyama, Hiroshi Sudo, Satoru Sawai, Kazuki Saito
  • Patent number: 8273562
    Abstract: A highly active L-isoleucine dioxygenase from Bacillus thuringiensis is provided. A method for manufacturing (2S,3R,4S)-4-hydroxy-L-isoleucine or a salt thereof by reacting L-isoleucine in an aqueous solvent in the presence of L-isoleucine dioxygenase and isolating (2S,3R,4S)-4-hydroxy-L-isoleucine is also provided.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: September 25, 2012
    Assignee: Ajinomoto Co., Inc.
    Inventors: Tomohiro Kodera, Sergey Vasilievich Smirnov, Natalia Nikolaevna Samsonova, Veronika Aleksandrovna Kotliarova, Natalia Yurievna Rushkevich, Yury Ivanovich Kozlov, Vitaly Grigorievich Paraskevov, legal representative, Sakayu Shimizu, Jun Ogawa, Makoto Hibi
  • Patent number: 8273554
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: September 25, 2012
    Assignee: Codexis, Inc.
    Inventors: Emily Mundorff, Erik De Vries
  • Patent number: 8273547
    Abstract: The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, method of using the engineered ketoreductase enzymes to synthesize a variety of chirally pure compounds, and the chirally pure compounds prepared therewith.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: September 25, 2012
    Assignee: Codexis, Inc.
    Inventors: Lorraine Joan Giver, Lisa Marie Newman, Emily Mundorff, Gjalt W. Huisman, Stephane J. Jenne, Jun Zhu, Behnaz Behrouzian, John H. Grate, James Lalonde
  • Publication number: 20120240248
    Abstract: The present invention relates to nucleic acids derived from Limonomyces roseipellis. The invention also relates to the individual coding sequences and to proteins encoded by these sequences as well to a process for converting oleic acid to linoleic acid to linoleic acid and the production of arachidonic acid, eicosapentaenoic acid and/or docosahexaenoic acid in a plant.
    Type: Application
    Filed: November 23, 2010
    Publication date: September 20, 2012
    Applicant: BASF Plant Science Company GmbH
    Inventors: Jörg Bauer, Xiao Qiu, Patricia Vrinten
  • Publication number: 20120233716
    Abstract: The present invention relates to nucleic acids derived from Sphaeroforma arctica. The invention also relates to the individual coding sequences and to proteins encoded by these sequences in combination with other sequences as well as to a process for converting oleic acid to linoleic acid to linoleic acid and the production of arachidonic acid, eicosapentaenoic acid and/or docosahexaenoic acid in a plant.
    Type: Application
    Filed: November 23, 2010
    Publication date: September 13, 2012
    Applicant: BASF Plant Science Company GmbH
    Inventors: Jörg Bauer, Xiao Qiu, Patricia Vrinten
  • Publication number: 20120231498
    Abstract: The invention is related to processing enzyme comprising an N-terminally attached tag derived from highly basic proteins from thermophilic bacteria. The processing enzymes are useful for modifying proteins. They can be produced in high yields and can be effectively separated from the modified protein after use.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 13, 2012
    Applicant: Novo Nordisk Health Care AG
    Inventor: Allan Christian Shaw
  • Patent number: 8263384
    Abstract: Novel organisms, including DNA construct host cell combinations, are disclosed. The organisms comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for enzymes which promote the supply of single carbon units for the conversion of dUMP to dTMP. Examples include: dihydrofolate reductase genes e.g. T4 frd; Serine Hydroxymethyltransferase genes e.g. glyA; 3-phosphoglycerate dehydrogenase genes e.g. serA; and THF synthase genes e.g. ADE3. The organisms are used in a biological method of producing thymidine with significantly reduced levels of uridine.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: September 11, 2012
    Assignee: Glaxo Group Limited
    Inventors: David Martin Anderson, Andrew John Collis, Lin Liu, Sergey Podkovyrov, Christopher Preston
  • Patent number: 8263326
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 8263373
    Abstract: Embodiments of the invention relate to the microbial production of polyhydroxyalkanoic acids, or polyhydroxyalkanoates (PHA), from substrates which cannot be used as a source of carbon and/or energy for microbial growth or PHA synthesis and which have microbial and environmental toxicity. According to one embodiment of the invention, a process for the production of PHA is provided wherein an enzyme such as methane monooxygenase is used to convert volatile organic compounds into PHA through the use of microorganisms that are unable to use volatile organic compounds as a source of carbon for growth or PHA production.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: September 11, 2012
    Assignee: Newlight Technologies, LLC
    Inventors: Markus Herrema, Kenton Kimmel
  • Patent number: 8263376
    Abstract: The present disclosure relates to an isolated lipoxygenase. The lipoxygenase of the present disclosure includes polypeptide with at least 80% sequence homology to the mature peptide shown in SEQ ID NO: 2. Lipoxygenase of the present disclosure is suitable for use in, among other things, baking and in detergent compositions.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: September 11, 2012
    Assignee: Novozymes A/S
    Inventors: Akiko Sugio, Shinobu Takagi